Article Text

Download PDFPDF
Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies

Statistics from


  • Competing interests: Hoffman-Roche provided free supplies of rituximab for the patients included in the study.

  • Funding: The study was supported by an unrestricted grant of Hoffman-Roche Ltd. The work of YKOT was supported by an Agiko grant from The Netherlands Organization for Scientific Research.

    Ethics approval was obtained.

  • Ethics approval: Ethics approval was obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.